Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended																	3 Months Ended	12 Months Ended
	Sep. 30, 2012		Sep. 30, 2011	Jun. 30, 2012		Sep. 30, 2012 Fair Value, Inputs, Level 1		Jun. 30, 2012 Fair Value, Inputs, Level 1		Sep. 30, 2012 Fair Value, Inputs, Level 2		Jun. 30, 2012 Fair Value, Inputs, Level 2		Sep. 30, 2012 Fair Value, Inputs, Level 3		Jun. 30, 2012 Fair Value, Inputs, Level 3		Sep. 30, 2012 P4 Healthcare	Jun. 30, 2012 P4 Healthcare
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Cash and Cash Equivalents, Fair Value Disclosure	$ 1,111	[1]		$ 997	[1]	$ 1,111	[1]	$ 997	[1]	$ 0	[1]	$ 0	[1]	$ 0	[1]	$ 0	[1]
Derivative Assets (Liabilities), at Fair Value, Net	13	[2]		49	[2]	0	[2]	0	[2]	13	[2]	49	[2]	0	[2]	0	[2]
Investments, Fair Value Disclosure	83	[3]		78	[3]	83	[3]	78	[3]	0	[3]	0	[3]	0	[3]	0	[3]
Business Acquisition, Contingent Consideration, at Fair Value	0	[4]		(4)	[4]	0	[4]	0	[4]	0	[4]	0	[4]	0	[4]	(4)	[4]
Total	1,207			1,120		1,194		1,075		13		49		0		(4)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability																			71
Payment Of Contingent Consideration	$ 4		$ 0															$ 4

[1] Cash equivalents are comprised of highly liquid investments purchased with a maturity of three months or less. The carrying value of these cash equivalents approximates fair value due to their short-term maturities.

[2] The fair value of foreign currency contracts, commodity contracts and interest rate swaps is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows.

[3] The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds primarily invest in the equity securities of companies with large market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.

[4] The contingent consideration obligation was incurred in connection with the acquisition of P4 Healthcare. The former owners of P4 Healthcare had the right to receive certain contingent payments based on targeted earnings before interest, taxes, depreciation and amortization ("EBITDA"). See Note 2 for additional information regarding the contingent consideration obligation related to the P4 Healthcare acquisition. The fair value of the contingent consideration obligation was determined based on a probability-weighted income approach derived from EBITDA estimates and probability assessments with respect to the likelihood of achieving the various EBITDA targets. The fair value measurement was based on significant inputs unobservable in the market and thus represented a Level 3 measurement. At each reporting date, we revalued the contingent consideration obligation to estimated fair value. Changes in the fair value of the contingent consideration obligation resulted from changes in the terms of the contingent payments, changes in discount periods and rates, changes in the timing and amount of EBITDA estimates, and changes in probability assumptions with respect to the timing and likelihood of achieving the EBITDA targets. As a result of changes in our estimate of performance in future periods, coupled with the progress of discussions with the former owners regarding an early termination and settlement, we recorded a $71 million total decrease in the fair value of the contingent consideration obligation primarily during the third and fourth quarters of fiscal 2012. We terminated and settled the remaining contingent consideration obligation in July 2012 for $4 million.